ResApp Health Limited announced SleepCheck, an at-home obstructive sleep apnoea (OSA) screening app. To be used directly by consumers, SleepCheck is an easy to use smartphone app that uses clinically accurate algorithms to assess a person's risk of OSA by analyzing their breathing and snoring sounds during sleep. SleepCheck requires no accessories or hardware other than the user's smartphone. Sleep apnoea is the most common sleep breathing disorder affecting more than three in every ten men and nearly two in every ten women. Sleep apnoea is when air stops flowing to a person's lungs for ten seconds or longer during sleep creating an apnoea event. In severe cases, this can happen more than 30 times per hour. Studies have shown that 80% of people with sleep apnoea are undiagnosed. Untreated, sleep apnoea has been linked to serious complications such as heart disease, hypertension, stroke and type 2 diabetes, and has a major impact on population health. Deloitte Access Economics estimates that OSA costs the Australian economy $21.2 billion annually. SleepCheck is a smartphone app that only requires a smartphone placed on the bedside table to assess a person's risk of OSA. In a 238 patient clinical study, ResApp's algorithms correctly identified patients with OSA with sensitivities of 85% (mild OSA), 83% (moderate OSA) and 83% (severe OSA), and specificities of 73%, 80% and 90% when compared to an American Academy of Sleep Medicine (AASM) Type II sleep study (full, but unattended polysomnography) performed simultaneously in the patient's home. SleepCheck is CE marked as a Class I medical device, which means it conforms to all European regulatory standards. SleepCheck will soon be listed on the Australian Register of Therapeutic Goods (ARTG). SleepCheck does not provide a diagnosis and is not intended as a substitute for a full sleep study using polysomnography. ResApp plans to launch SleepCheck for iOS on the App Store in the United Kingdom and Australia in the second quarter of this calendar year, with availability in additional countries and an Android version to follow. Pricing is still to be determined. Sleep apnoea is a common sleep disorder where the person repeatedly stops breathing or has periods of shallow breathing during sleep. Data from the Wisconsin Sleep Cohort Study showed that sleep apnoea affects more than three in ten men and nearly two in ten women. 80% of people suffering moderate and severe sleep apnoea are undiagnosed. Untreated, obstructive sleep apnoea is known to increase the risk of heart disease, hypertension, stroke and type 2 diabetes, and is estimated by the American Academy of Sleep Medicine to cost the US economy $149.6 billion annually.